AZD4017 and prednisolone + Placebo Oral Tablet and prednisolone
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Iatrogenic Cushing's Disease
Conditions
Iatrogenic Cushing's Disease
Trial Timeline
May 25, 2017 → Aug 1, 2020
NCT ID
NCT03111810About AZD4017 and prednisolone + Placebo Oral Tablet and prednisolone
AZD4017 and prednisolone + Placebo Oral Tablet and prednisolone is a phase 2 stage product being developed by AstraZeneca for Iatrogenic Cushing's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03111810. Target conditions include Iatrogenic Cushing's Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03111810 | Phase 2 | Completed |